-
1
-
-
84865442957
-
Ammonia-lowering strategies for the treatment of hepatic encephalopathy
-
Rose CF. Ammonia-lowering strategies for the treatment of hepatic encephalopathy. Clin Pharmacol Ther 2012; 92: 321-31.
-
(2012)
Clin Pharmacol Ther
, vol.92
, pp. 321-331
-
-
Rose, C.F.1
-
2
-
-
85080034819
-
Pathogenetic mechanisms of hepatic encephalopathy
-
Häussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008; 57: 1156-65.
-
(2008)
Gut
, vol.57
, pp. 1156-1165
-
-
Häussinger, D.1
Schliess, F.2
-
3
-
-
77956393999
-
Mechanisms, diagnosis and management of hepatic encephalopathy
-
Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010; 7: 515-25.
-
(2010)
Nat Rev Gastroenterol Hepatol
, vol.7
, pp. 515-525
-
-
Prakash, R.1
Mullen, K.D.2
-
4
-
-
58049083992
-
Pathophysiology of hepatic encephalopathy: The concept of synergism
-
Butterworth RF. Pathophysiology of hepatic encephalopathy: The concept of synergism. Hepatol Res 2008; 38: S116-21.
-
(2008)
Hepatol Res
, vol.38
, pp. S116-S121
-
-
Butterworth, R.F.1
-
5
-
-
33845637697
-
CAPPS Investigators. Hyponatremia in cirrhosis: Results of a patient population survey
-
Angeli P, Wong F, Watson H, Ginès P. CAPPS Investigators. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology 2006; 44: 1535-42.
-
(2006)
Hepatology
, vol.44
, pp. 1535-1542
-
-
Angeli, P.1
Wong, F.2
Watson, H.3
Ginès, P.4
-
6
-
-
51349142798
-
Hyponatremia in cirrhosis: Pathogenesis, clinical significance, and management
-
Ginès P, Guevara M. Hyponatremia in cirrhosis: Pathogenesis, clinical significance, and management. Hepatology 2008; 48: 1002-10.
-
(2008)
Hepatology
, vol.48
, pp. 1002-1010
-
-
Ginès, P.1
Guevara, M.2
-
7
-
-
84869231273
-
Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema
-
Solà E, Watson H, Graupera I et al. Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. J Hepatol 2012; 57: 1199-206.
-
(2012)
J Hepatol
, vol.57
, pp. 1199-1206
-
-
Solà, E.1
Watson, H.2
Graupera, I.3
-
8
-
-
77954145023
-
Organic osmolytes in hyponatremia and ammonia toxicity
-
Heins J, Zwingmann C. Organic osmolytes in hyponatremia and ammonia toxicity. Metab Brain Dis 2010; 25: 81-9.
-
(2010)
Metab Brain Dis
, vol.25
, pp. 81-89
-
-
Heins, J.1
Zwingmann, C.2
-
9
-
-
77954143273
-
Hyponatremic and hepatic encephalopathies: similarities, differences and coexistence
-
Córdoba J, García-Martinez R, Simón-Talero M. Hyponatremic and hepatic encephalopathies: similarities, differences and coexistence. Metab Brain Dis 2010; 25: 73-80.
-
(2010)
Metab Brain Dis
, vol.25
, pp. 73-80
-
-
Córdoba, J.1
García-Martinez, R.2
Simón-Talero, M.3
-
10
-
-
77950246404
-
Rifaximin treatment in hepatic encephalopathy
-
Bass NM, Mullen KD, Sanyal A et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-81.
-
(2010)
N Engl J Med
, vol.362
, pp. 1071-1081
-
-
Bass, N.M.1
Mullen, K.D.2
Sanyal, A.3
-
11
-
-
84857577254
-
Rifaximin vs. conventional oral therapy for hepatic encephalopathy: A meta-analysis
-
Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: A meta-analysis. World J Gastroenterol 2012; 18: 767-77.
-
(2012)
World J Gastroenterol
, vol.18
, pp. 767-777
-
-
Eltawil, K.M.1
Laryea, M.2
Peltekian, K.3
Molinari, M.4
-
12
-
-
84890930202
-
Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial
-
Sakaida I, Kawazoe S, Kajimura K et al. Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res 2014; 44: 73-82.
-
(2014)
Hepatol Res
, vol.44
, pp. 73-82
-
-
Sakaida, I.1
Kawazoe, S.2
Kajimura, K.3
-
13
-
-
0023277382
-
Biochemistry and physiology of brain ammonia
-
Cooper AJ, Plum F. Biochemistry and physiology of brain ammonia. Physiol Rev 1987; 67: 440-519.
-
(1987)
Physiol Rev
, vol.67
, pp. 440-519
-
-
Cooper, A.J.1
Plum, F.2
-
14
-
-
0343238857
-
Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?
-
Häussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 2000; 32: 1035-8.
-
(2000)
J Hepatol
, vol.32
, pp. 1035-1038
-
-
Häussinger, D.1
Kircheis, G.2
Fischer, R.3
Schliess, F.4
vom Dahl, S.5
-
15
-
-
20444366546
-
Acute insult of ammonia leads to calcium-dependent glutamate release from cultured astrocytes, an effect of pH
-
Rose C, Kresse W, Kettenmann H. Acute insult of ammonia leads to calcium-dependent glutamate release from cultured astrocytes, an effect of pH. J Biol Chem 2005; 280: 20937-44.
-
(2005)
J Biol Chem
, vol.280
, pp. 20937-20944
-
-
Rose, C.1
Kresse, W.2
Kettenmann, H.3
-
16
-
-
0036981517
-
1H magnetic resonance in the study of hepatic encephalopathy in humans
-
Córdoba J, Sanpedro F, Alonso J, Rovira A. 1H magnetic resonance in the study of hepatic encephalopathy in humans. Metab Brain Dis 2002; 17: 415-29.
-
(2002)
Metab Brain Dis
, vol.17
, pp. 415-429
-
-
Córdoba, J.1
Sanpedro, F.2
Alonso, J.3
Rovira, A.4
-
17
-
-
0028037077
-
Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy
-
Häussinger D, Laubenberger J, vom Dahl S et al. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology 1994; 107: 1475-80.
-
(1994)
Gastroenterology
, vol.107
, pp. 1475-1480
-
-
Häussinger, D.1
Laubenberger, J.2
vom Dahl, S.3
-
18
-
-
84871410392
-
Regional reduction in gray and white matter volume in brains of cirrhotic patients: Voxel-based analysis of MRI
-
Iwasa M, Mifuji-Moroka R, Kuroda M et al. Regional reduction in gray and white matter volume in brains of cirrhotic patients: Voxel-based analysis of MRI. Metab Brain Dis 2012; 27: 551-7.
-
(2012)
Metab Brain Dis
, vol.27
, pp. 551-557
-
-
Iwasa, M.1
Mifuji-Moroka, R.2
Kuroda, M.3
-
19
-
-
44949241302
-
Value of the apparent diffusion coefficient for quantification of low-grade hepatic encephalopathy
-
Sugimoto R, Iwasa M, Maeda M et al. Value of the apparent diffusion coefficient for quantification of low-grade hepatic encephalopathy. Am J Gastroenterol 2008; 103: 1413-20.
-
(2008)
Am J Gastroenterol
, vol.103
, pp. 1413-1420
-
-
Sugimoto, R.1
Iwasa, M.2
Maeda, M.3
-
20
-
-
0033366776
-
Magnetization transfer contrast of various regions of the brain in liver cirrhosis
-
Iwasa M, Kinosada Y, Nakatsuka A, Watanabe S, Adachi Y. Magnetization transfer contrast of various regions of the brain in liver cirrhosis. AJNR Am J Neuroradiol 1999; 20: 652-4.
-
(1999)
AJNR Am J Neuroradiol
, vol.20
, pp. 652-654
-
-
Iwasa, M.1
Kinosada, Y.2
Nakatsuka, A.3
Watanabe, S.4
Adachi, Y.5
-
21
-
-
70349497154
-
Reversible cytotoxic edema in a cirrhotic patient following TIPS
-
Babington JR, Stahl JH, Coy DL. Reversible cytotoxic edema in a cirrhotic patient following TIPS. J Neuroimaging 2009; 19: 391-3.
-
(2009)
J Neuroimaging
, vol.19
, pp. 391-393
-
-
Babington, J.R.1
Stahl, J.H.2
Coy, D.L.3
-
22
-
-
50649113720
-
Cerebral edema and hyperammonemia after transjugular intrahepatic portosystemic shunt placement in a cirrhotic patient
-
Kavitt RT, Yang VL, Jensen DM. Cerebral edema and hyperammonemia after transjugular intrahepatic portosystemic shunt placement in a cirrhotic patient. Clin Gastroenterol Hepatol 2008; 6: 1054-6.
-
(2008)
Clin Gastroenterol Hepatol
, vol.6
, pp. 1054-1056
-
-
Kavitt, R.T.1
Yang, V.L.2
Jensen, D.M.3
-
23
-
-
79956074041
-
Magnetic resonance quantification of water and metabolites in the brain of cirrhotics following induced hyperammonaemia
-
Mardini H, Smith FE, Record CO, Blamire AM. Magnetic resonance quantification of water and metabolites in the brain of cirrhotics following induced hyperammonaemia. J Hepatol 2011; 54: 1154-60.
-
(2011)
J Hepatol
, vol.54
, pp. 1154-1160
-
-
Mardini, H.1
Smith, F.E.2
Record, C.O.3
Blamire, A.M.4
-
25
-
-
1642491776
-
Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis
-
Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004; 40: 247-54.
-
(2004)
J Hepatol
, vol.40
, pp. 247-254
-
-
Shawcross, D.L.1
Davies, N.A.2
Williams, R.3
Jalan, R.4
-
26
-
-
0035888288
-
Ammonia-induced production of free radicals in primary cultures of rat astrocytes
-
Murthy CR, Rama Rao KV, Bai G, Norenberg MD. Ammonia-induced production of free radicals in primary cultures of rat astrocytes. J Neurosci Res 2001; 66: 282-8.
-
(2001)
J Neurosci Res
, vol.66
, pp. 282-288
-
-
Murthy, C.R.1
Rama Rao, K.V.2
Bai, G.3
Norenberg, M.D.4
-
27
-
-
79955753653
-
Current concepts in the pathophysiology and management of hepatic encephalopathy
-
Frederick RT. Current concepts in the pathophysiology and management of hepatic encephalopathy. Gastroenterol Hepatol (N Y) 2011; 7: 222-33.
-
(2011)
Gastroenterol Hepatol (N Y)
, vol.7
, pp. 222-233
-
-
Frederick, R.T.1
-
28
-
-
84873098297
-
Value of diffusion-weighted imaging in central pontine and extrapontine myelinolysis
-
Förster A, Nölte I, Wenz H et al. Value of diffusion-weighted imaging in central pontine and extrapontine myelinolysis. Neuroradiology 2013; 55: 49-56.
-
(2013)
Neuroradiology
, vol.55
, pp. 49-56
-
-
Förster, A.1
Nölte, I.2
Wenz, H.3
-
29
-
-
67349206170
-
Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: A prospective study with time-dependent analysis
-
Guevara M, Baccaro ME, Torre A et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: A prospective study with time-dependent analysis. Am J Gastroenterol 2009; 104: 1382-9.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 1382-1389
-
-
Guevara, M.1
Baccaro, M.E.2
Torre, A.3
-
30
-
-
84901412215
-
Patients with hyponatremic cirrhosis have low-grade cerebral edema and poor quality-of-life
-
Iwasa M, Sugimoto R, Takei Y. Patients with hyponatremic cirrhosis have low-grade cerebral edema and poor quality-of-life. Ann Hepatol 2014; 13: 407-8.
-
(2014)
Ann Hepatol
, vol.13
, pp. 407-408
-
-
Iwasa, M.1
Sugimoto, R.2
Takei, Y.3
-
31
-
-
0034933478
-
Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients
-
Amodio P, Del Piccolo F, Pettenò E et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol 2001; 35: 37-45.
-
(2001)
J Hepatol
, vol.35
, pp. 37-45
-
-
Amodio, P.1
Del Piccolo, F.2
Pettenò, E.3
-
32
-
-
0029161548
-
Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage
-
Jalan R, Elton RA, Redhead DN, Finlayson ND, Hayes PC. Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage. J Hepatol 1995; 23: 123-8.
-
(1995)
J Hepatol
, vol.23
, pp. 123-128
-
-
Jalan, R.1
Elton, R.A.2
Redhead, D.N.3
Finlayson, N.D.4
Hayes, P.C.5
-
33
-
-
79851509612
-
Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration
-
Guevara M, Baccaro ME, Ríos J et al. Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int 2010; 30: 1137-42.
-
(2010)
Liver Int
, vol.30
, pp. 1137-1142
-
-
Guevara, M.1
Baccaro, M.E.2
Ríos, J.3
-
34
-
-
84876986629
-
Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: A preliminary, prospective, open-label study
-
Kato A, Tanaka H, Kawaguchi T et al. Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: A preliminary, prospective, open-label study. Hepatol Res 2013; 43: 452-8.
-
(2013)
Hepatol Res
, vol.43
, pp. 452-458
-
-
Kato, A.1
Tanaka, H.2
Kawaguchi, T.3
-
35
-
-
84882915250
-
Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis
-
Ahluwalia V, Wade JB, Thacker L et al. Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis. J Hepatol 2013; 59: 467-73.
-
(2013)
J Hepatol
, vol.59
, pp. 467-473
-
-
Ahluwalia, V.1
Wade, J.B.2
Thacker, L.3
-
36
-
-
0034053858
-
Nutritional treatment with branched-chain amino acids in advanced liver cirrhosis
-
Marchesini G, Bianchi G, Rossi B, Brizi M, Melchionda N. Nutritional treatment with branched-chain amino acids in advanced liver cirrhosis. J Gastroenterol 2000; 35: 7-12.
-
(2000)
J Gastroenterol
, vol.35
, pp. 7-12
-
-
Marchesini, G.1
Bianchi, G.2
Rossi, B.3
Brizi, M.4
Melchionda, N.5
-
37
-
-
84884926712
-
Nutrition therapy using a multidisciplinary team improves survival rates in patients with liver cirrhosis
-
Iwasa M, Iwata K, Hara N et al. Nutrition therapy using a multidisciplinary team improves survival rates in patients with liver cirrhosis. Nutrition 2013; 29: 1418-21.
-
(2013)
Nutrition
, vol.29
, pp. 1418-1421
-
-
Iwasa, M.1
Iwata, K.2
Hara, N.3
-
38
-
-
2342487336
-
Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials
-
Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328: 1046.
-
(2004)
BMJ
, vol.328
, pp. 1046
-
-
Als-Nielsen, B.1
Gluud, L.L.2
Gluud, C.3
-
39
-
-
77950949259
-
Considerations on the impact of hepatic encephalopathy treatments in the pretransplant setting
-
Teperman LW, Peyregne VP. Considerations on the impact of hepatic encephalopathy treatments in the pretransplant setting. Transplantation 2010; 89: 771-8.
-
(2010)
Transplantation
, vol.89
, pp. 771-778
-
-
Teperman, L.W.1
Peyregne, V.P.2
-
40
-
-
77950586321
-
Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients
-
Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther 2010; 31: 1012-7.
-
(2010)
Aliment Pharmacol Ther
, vol.31
, pp. 1012-1017
-
-
Bajaj, J.S.1
Sanyal, A.J.2
Bell, D.3
Gilles, H.4
Heuman, D.M.5
-
41
-
-
84875670330
-
Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy
-
Bajaj JS, Heuman DM, Sanyal AJ et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013; 8: e60042.
-
(2013)
PLoS One
, vol.8
, pp. e60042
-
-
Bajaj, J.S.1
Heuman, D.M.2
Sanyal, A.J.3
-
42
-
-
84874396873
-
Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis
-
Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 2013; 28: 450-5.
-
(2013)
J Gastroenterol Hepatol
, vol.28
, pp. 450-455
-
-
Vlachogiannakos, J.1
Viazis, N.2
Vasianopoulou, P.3
Vafiadis, I.4
Karamanolis, D.G.5
Ladas, S.D.6
-
43
-
-
84873587829
-
Rifaximin therapy and hepatic encephalopathy: Pros and cons
-
Zullo A, Hassan C, Ridola L, Lorenzetti R, Campo SM, Riggio O. Rifaximin therapy and hepatic encephalopathy: Pros and cons. World J Gastrointest Pharmacol Ther 2012; 3: 62-7.
-
(2012)
World J Gastrointest Pharmacol Ther
, vol.3
, pp. 62-67
-
-
Zullo, A.1
Hassan, C.2
Ridola, L.3
Lorenzetti, R.4
Campo, S.M.5
Riggio, O.6
-
44
-
-
84859133780
-
Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis
-
Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology 2012; 55: 1164-71.
-
(2012)
Hepatology
, vol.55
, pp. 1164-1171
-
-
Bajaj, J.S.1
Pinkerton, S.D.2
Sanyal, A.J.3
Heuman, D.M.4
-
45
-
-
0038047688
-
Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: A double-blind, randomized trial
-
Marchesini G, Bianchi G, Merli M et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: A double-blind, randomized trial. Gastroenterology 2003; 124: 1792-801.
-
(2003)
Gastroenterology
, vol.124
, pp. 1792-1801
-
-
Marchesini, G.1
Bianchi, G.2
Merli, M.3
-
46
-
-
84884300560
-
Effects of oral branched-chain amino acids on hepatic encephalopathy and outcome in patients with liver cirrhosis
-
Kawaguchi T, Taniguchi E, Sata M. Effects of oral branched-chain amino acids on hepatic encephalopathy and outcome in patients with liver cirrhosis. Nutr Clin Pract 2013; 28: 580-8.
-
(2013)
Nutr Clin Pract
, vol.28
, pp. 580-588
-
-
Kawaguchi, T.1
Taniguchi, E.2
Sata, M.3
-
47
-
-
0025150823
-
Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group
-
Marchesini G, Dioguardi FS, Bianchi GP et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol 1990; 11: 92-101.
-
(1990)
J Hepatol
, vol.11
, pp. 92-101
-
-
Marchesini, G.1
Dioguardi, F.S.2
Bianchi, G.P.3
-
48
-
-
84881361645
-
Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials
-
Gluud LL, Dam G, Borre M et al. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr 2013; 143: 1263-8.
-
(2013)
J Nutr
, vol.143
, pp. 1263-1268
-
-
Gluud, L.L.1
Dam, G.2
Borre, M.3
-
49
-
-
79961017249
-
Branched-chain amino acids increase arterial blood ammonia in spite of enhanced intrinsic muscle ammonia metabolism in patients with cirrhosis and healthy subjects
-
Dam G, Keiding S, Munk OL et al. Branched-chain amino acids increase arterial blood ammonia in spite of enhanced intrinsic muscle ammonia metabolism in patients with cirrhosis and healthy subjects. Am J Physiol Gastrointest Liver Physiol 2011; 301: G269-77.
-
(2011)
Am J Physiol Gastrointest Liver Physiol
, vol.301
, pp. G269-G277
-
-
Dam, G.1
Keiding, S.2
Munk, O.L.3
-
50
-
-
84878016950
-
Acetyl-L-carnitine in hepatic encephalopathy
-
Malaguarnera M. Acetyl-L-carnitine in hepatic encephalopathy. Metab Brain Dis 2013; 28: 193-9.
-
(2013)
Metab Brain Dis
, vol.28
, pp. 193-199
-
-
Malaguarnera, M.1
-
51
-
-
84878015722
-
Possible treatment of end-stage hyperammonemic encephalopathy by inhibition of glutamine synthetase
-
Cooper AJ. Possible treatment of end-stage hyperammonemic encephalopathy by inhibition of glutamine synthetase. Metab Brain Dis 2013; 28: 119-25.
-
(2013)
Metab Brain Dis
, vol.28
, pp. 119-125
-
-
Cooper, A.J.1
-
52
-
-
84883744232
-
A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy
-
Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013; 108: 1458-63.
-
(2013)
Am J Gastroenterol
, vol.108
, pp. 1458-1463
-
-
Sharma, B.C.1
Sharma, P.2
Lunia, M.K.3
Srivastava, S.4
Goyal, R.5
Sarin, S.K.6
-
53
-
-
67651053228
-
Branched chain amino acids supplemented with L-acetylcarnitine versus BCAA treatment in hepatic coma: a randomized and controlled double blind study
-
Malaguarnera M, Risino C, Cammalleri L et al. Branched chain amino acids supplemented with L-acetylcarnitine versus BCAA treatment in hepatic coma: a randomized and controlled double blind study. Eur J Gastroenterol Hepatol 2009; 21: 762-70.
-
(2009)
Eur J Gastroenterol Hepatol
, vol.21
, pp. 762-770
-
-
Malaguarnera, M.1
Risino, C.2
Cammalleri, L.3
-
54
-
-
79951678831
-
Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy
-
Shukla S, Shukla A, Mehboob S, Guha S. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment Pharmacol Ther 2011; 33: 662-71.
-
(2011)
Aliment Pharmacol Ther
, vol.33
, pp. 662-671
-
-
Shukla, S.1
Shukla, A.2
Mehboob, S.3
Guha, S.4
-
55
-
-
84898830272
-
Altered profile of human gut microbiome is associated with cirrhosis and its complications
-
Bajaj JS, Heuman DM, Hylemon PB et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60: 940-7.
-
(2014)
J Hepatol
, vol.60
, pp. 940-947
-
-
Bajaj, J.S.1
Heuman, D.M.2
Hylemon, P.B.3
-
56
-
-
84901200252
-
Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial
-
Lunia MK, Sharma BC, Sharma P, Sachdeva S, Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol 2014; 12: 1003-8.
-
(2014)
Clin Gastroenterol Hepatol
, vol.12
, pp. 1003-1008
-
-
Lunia, M.K.1
Sharma, B.C.2
Sharma, P.3
Sachdeva, S.4
Srivastava, S.5
-
57
-
-
84866245430
-
Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia
-
Dahl E, Gluud LL, Kimer N, Krag A. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. Aliment Pharmacol Ther 2012; 36: 619-26.
-
(2012)
Aliment Pharmacol Ther
, vol.36
, pp. 619-626
-
-
Dahl, E.1
Gluud, L.L.2
Kimer, N.3
Krag, A.4
|